Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

Mathias W. R. Pletz, Andres De Roux, Andreas Roth, Karl-Heinz Neumann, Harald Mauch, Hartmut Lode
Mathias W. R. Pletz
1Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mpletz@sph.emory.edu
Andres De Roux
1Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Roth
2Institute of Microbiology, City Hospital Emil von Behring, Freie Universität Berlin, 14195 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl-Heinz Neumann
1Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harald Mauch
2Institute of Microbiology, City Hospital Emil von Behring, Freie Universität Berlin, 14195 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hartmut Lode
1Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.48.3.780-782.2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Moxifloxacin is the most active fluoroquinolone against Mycobacterium tuberculosis in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log10 CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid.

Tuberculosis remains one of the deadliest diseases in the world. The World Health Organization (WHO) estimates that more than 8 million new cases of tuberculosis occur each year, and approximately 3 million people die from the disease.

The emerging resistance of Mycobacterium tuberculosis to standard antituberculous drugs raises the need for the development of new agents. Fluoroquinolones are of particular interest, because there is no indication of cross-resistance to other antituberculous drugs (9). The clinical efficacy of ciprofloxacin and ofloxacin has already been proven in studies, and despite limited bactericidal activity, these drugs are recommended as second-line therapy by WHO (1). To date, moxifloxacin and gatifloxacin have been shown to be the most active fluoroquinolones against M. tuberculosis in vitro (2, 5), and moxifloxacin’s antimycobacterial activity has been confirmed in animal studies (12, 14). However, data about the efficacy in patients are not available.

Early bactericidal activity (EBA) of antituberculosis drugs is the rate of decrease in the concentration of tubercle bacilli in sputum during the initial days of therapy and is used to assess the potency of new antituberculous drugs in clinical studies (6).

MATERIALS AND METHODS

We performed a randomized, open, single-center study at the Chest Hospital Heckeshorn, Berlin, Germany, to assess the clinical efficacy of moxifloxacin in patients with pulmonary tuberculosis. The protocol was approved by the Ethical Committee of the Freie Universität, Berlin, and written informed consent was obtained from all subjects prior to enrollment. Seventeen adult, nonimmunocompromised patients with smear-positive pulmonary tuberculosis and radiological evidence of an infiltrate were orally treated with either 400 mg of moxifloxacin (Bayer, Wuppertal, Germany) once daily (n = 8) or 6-mg/kg isoniazid (INH) (Fatol, Schiffsweiler, Germany) (n = 9) for 5 days. Patients who had received a previous antituberculous chemotherapy within the last 2 years, patients pretreated with any systemic antibacterial agent within 48 h prior to enrollment, and patients requiring concomitant systemic antibacterial therapy were excluded. The study treatment period was followed by a standard therapeutic regimen for 6 months. Sputum was collected from 4:00 p.m. to 8:00 a.m. before treatment (baseline) and after 2 and 5 days of study treatment. Hematological and biochemistry parameters were assessed simultaneously, and electrocardiogram measuring was performed. The count of CFU per milliliter was determined as described previously (11). The EBA was calculated for each patient by the formula (log CFU/mlday0 − log CFU/mlday5)/5 and is given as the mean ± standard deviation (SD). As recommended by several authors, we defined the EBA as the decrease in log10 CFU per milliliter of sputum per day during the first 5 days of treatment (3, 4).

The numbers of CFU per milliliter before therapy and after 2 and 5 days of study treatment were compared by Wilcoxon's test. The EBAs of moxifloxacin and INH were compared by the Mann-Whitney U test. Statistical analysis was performed with SPSS 11.0 for Windows.

RESULTS AND DISCUSSION

Demographic data of enrolled patients are given in Table 1. Two patients in the moxifloxacin-treated group reported a previous therapy against tuberculosis: One was treated 3 years prior to enrollment with a combination of INH, rifampin, pyrazinamide, and ethambutol. The other patient was treated 12 years prior to study enrollment. Further details about the specific treatment of this patient were not available.

View this table:
  • View inline
  • View popup
TABLE 1.

Patients' characteristics

All patients completed the study. Medication was well tolerated in both groups. No clinically relevant changes in laboratory and ECG parameters (particularly no QT-interval extension) were recorded. Antibiotic susceptibility testing revealed no evidence of resistance to either moxifloxacin or the standard antituberculous drugs (INH, rifampin, ethambutol, pyrazinamide, and streptomycin) in any patient. The INH MIC was ≤0.125 mg/liter in all patients. The distribution of moxifloxacin MICs in both treatment groups is given in Table 2.

View this table:
  • View inline
  • View popup
TABLE 2.

Distribution of moxifloxacin MICs in both treatment groups

The baseline numbers of CFU per milliliter in sputum in the moxifloxacin-treated and INH-treated groups are shown in Table 3. In both groups, a significant decrease in CFU per milliliter in sputum compared to baseline was detected after 5 days of study treatment (Wilcoxon test P values for moxifloxacin and INH = 0.028 and 0.015, respectively). Whereas this was to be expected for INH, this is the first evidence for the clinical efficacy of moxifloxacin in patients. In contrast to moxifloxacin, INH treatment led to a faster reduction of the bacterial load already after 2 days of treatment. Nevertheless, the antimycobacterial effect of moxifloxacin seems to be similar to that of INH after 5 days of treatment. The reason for the delayed effect of moxifloxacin compared to that of INH might be due to the different mechanism of action: INH interferes with mycolic acid biosynthesis (13), whereas moxifloxacin mainly affects replicating bacteria by binding to DNA gyrase and topoisomerase IV (8).

View this table:
  • View inline
  • View popup
TABLE 3.

Change in CFU per milliliter of sputum and EBA in both treatment groups

The calculated mean EBAs (with 95% confidence intervals [CIs] in parentheses) for INH and moxifloxacin were 0.209 (0.009, 0.394) and 0.273 (0.0001, 0.5462) log10 CFU per ml of sputum per day, respectively. There were no significant differences between the EBAs (P = 0.722, Mann-Whitney U test).

Despite the limited number of patients, these data suggest that the antimycobacterial activity of moxifloxacin is, with a delay of its onset, similar to that of INH. Different studies determined different EBAs for the same drug and dosage. Therefore, it is important to relate the results of a new drug to a comparator drug (mostly INH) tested in the same study. The EBA of INH (6 mg/kg) has been described in other studies with results of between 1.01 (11 patients) (11) and 0.21 (16 patients) log10 CFU per ml of sputum per day (4). This relative wide dispersion may be caused by different methodologies—such as, for instance, duration of sputum collection (4)—and by the demographic parameters of the different study populations. Most of the studies that revealed a particularly high EBA for INH were conducted in countries with a high incidence of tuberculosis. The patients enrolled in these studies were mainly younger, had a lighter body weight, and presented a higher pretreatment count of CFU per milliliter than that in patients enrolled in studies in low-incidence countries. This may lead to higher concentrations of the drug in tissue, since the dose of orally administered drugs was not adjusted for body weight (10), and higher pretreatment counts of CFU per milliliter might emphasize the decrease after initial therapy. A multicenter study performed by Sirgel et al. (11) supports the fact that the environment and study population influence the EBA result. In this study, the pretreatment CFU count in the patients in Hong Kong was markedly lower than the pretreatment counts in the patients in the other study centers (Cape Town, South Africa, Nairobi, Kenya, and Madras, India). In consequence, the EBA for INH (at 300 mg) was remarkably lower in the Hong Kong patients (0.37 versus 0.64 to 1.01 log10 CFU per ml of sputum per day) despite an identical methodology.

The EBA for INH in our study (0.209 log10 CFU per ml of sputum per day) corresponds very well with the data from the U.S. study by Hafner et al. mentioned above(4).

However, the EBA of moxifloxacin in our study was even greater than that of the comparator drug, whereas in other studies, INH was revealed to be the most powerful antimycobacterial drug (11). Due to the labor-intensive setting, most studies assessing the EBA, including ours, enroll only a small number of patients, and studies with higher numbers of patients might be needed. Despite this situation, our data demonstrate the already presumed clinical efficacy of moxifloxacin in pulmonary tuberculosis. The calculation of the 95% CI of the difference between the EBA of moxifloxacin and INH (−0.337 to 0.210) revealed that moxifloxacin had at least 61.6% of the antimycobacterial activity of INH in our study. In fact, moxifloxacin is already used as a second-line drug for treatment of tuberculosis in particular cases. Moxifloxacin might be useful for the treatment of multidrug-resistant tuberculosis, because no cross-resistance to other classes of antituberculous drugs is known. Other aspects to consider are the possible side effects of moxifloxacin long-term treatment, which would be required for tuberculosis. Compared to the classic antituberculous drugs, fluoroquinolones can be considered to be better tolerated. However, as yet, there are only limited data to support this issue, and therefore precautions should be taken, particularly when combining fluoroquinolones with other antituberculous drugs (7).

ACKNOWLEDGMENTS

The study was supported by a grant from Bayer Vital GmbH, Germany. Mathias W. Pletz was supported by the German Research Foundation.

We thank Gisela Korfmann, Keith P. Klugman, Lesley McGee, and Peter Reimnitz for critical reading of the manuscript. The technical assistance of Gudrun Bettermann, Birgit Howe, and Tessa Ziemssen is gratefully acknowledged.

FOOTNOTES

    • Received 18 August 2003.
    • Returned for modification 14 October 2003.
    • Accepted 11 November 2003.
  • Copyright © 2004 American Society for Microbiology

REFERENCES

  1. 1.↵
    Crofton, J., P. Chaulet, and D. Maher. 1997. Guidelines for the managment of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
  2. 2.↵
    Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother.44:393-395.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Gillespie, S. H., R. D. Gosling, and B. M. Charalambous. 2002. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Am. J. Respir. Crit. Care Med.166:31-35.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Hafner, R., J. A. Cohn, D. J. Wright, N. E. Dunlap, M. J. Egorin, M. E. Enama, K. Muth, C. A. Peloquin, N. Mor, L. B. Heifets, et al. 1997. Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. Am. J. Respir. Crit. Care Med.156:918-923.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Hu, Y., A. R. M. Coates, and D. A. Mitchison. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.47:653-657.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis.121:939-949.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Papastavros, T., L. R. Dolovich, A. Holbrook, L. Whitehead, and M. Loeb. 2002. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Can. Med. Assoc. J.167:131-136.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Pestova, E., J. J. Millichap, G. A. Noskin, and L. R. Peterson. 2000. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother.45:583-590.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Rodriguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents20:464-467.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Sirgel, F., A. Venter, and D. Mitchison. 2001. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J. Antimicrob. Chemother.47:177-182.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Sirgel, F. A., P. R. Donald, J. Odhiambo, W. Githui, K. C. Umapathy, C. N. Paramasivan, C. M. Tam, K. M. Kam, C. W. Lam, K. M. Sole, and D. A. Mitchison. 2000. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J. Antimicrob. Chemother.45:859-870.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Veziris, N., C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother.47:3117-3122.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Winder, F. G. 1982. Mode of action of antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria, p. 353-438. In C. Ratledge and J. Standford (ed.), The biology of the mycobacteria. Academic Press, London, United Kingdom.
  14. 14.↵
    Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother.46:1875-1879.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study
Mathias W. R. Pletz, Andres De Roux, Andreas Roth, Karl-Heinz Neumann, Harald Mauch, Hartmut Lode
Antimicrobial Agents and Chemotherapy Feb 2004, 48 (3) 780-782; DOI: 10.1128/AAC.48.3.780-782.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study
Mathias W. R. Pletz, Andres De Roux, Andreas Roth, Karl-Heinz Neumann, Harald Mauch, Hartmut Lode
Antimicrobial Agents and Chemotherapy Feb 2004, 48 (3) 780-782; DOI: 10.1128/AAC.48.3.780-782.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS AND DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

anti-infective agents
Aza Compounds
quinolines
Tuberculosis, Pulmonary

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596